Omeros | OMER - Ebit


Omeros reported $-48.15M in EBIT for its fiscal quarter ending in September of 2023.





Ebit Change Date
Adma Biologics USD 59.23M 3.52M Mar/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Cytokinetics USD -179.17M 2.05M Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Immunic USD -23.33M 2.67M Dec/2025
Insmed USD -101.31M 98.97M Jun/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
MacroGenics USD -31.88M 19.79M Mar/2026
Omeros USD -48.15M 7.25M Sep/2023
Pacira USD 9.96M 5.33M Jun/2026
Pfizer USD -180M 5.16B Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
United Therapeutics USD 375.6M 49.8M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026